PEMFEXY™ is a folate analog metabolic inhibitor indicated for:...in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumor aberrations.

Pemetrexed Injection is a folate analog metabolic inhibitor indicated...in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC)...

Keytruda, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non squamous non small cell lung carcinoma in adults whose tumours have no EGFR or ALK positive mutations.

KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated:…in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations.

A potentially life-extending treatment for some people with non-squamous, non-small-cell lung cancer (NSCLC) will now be available on the NHS following its approval by NICE in draft guidance published today....The draft guidance means pembrolizumab...with pemetrexed and platinum chemotherapy will be available as a first-line treatment option for adults whose tumors have no...(EGFR)-positive or...(ALK)-positive mutations.

…pembrolizumab/chemotherapy regimens are recommended (category 1; preferred) as first-line therapy options for patients with metastatic nonsquamous NSCLC...Maintenance therapy with pembrolizumab/pemetrexed is also a recommended option (category 1)…

Pemetrexed and platinum plus pembrolizumab were found to have relevant efficacy regardless of the extent of baseline tumor burden and the variables used to define it. These results further support pemetrexed and platinum plus pembrolizumab as the standard of care in the first-line treatment of metastatic nonsquamous NSCLC.

In the phase III KEYNOTE-189 study (NCT02578680), pembrolizumab plus pemetrexed and platinum-based chemotherapy (pemetrexed-platinum) significantly improved overall survival (OS) and progression-free survival (PFS)...We report updated efficacy outcomes from the protocol-specified final analysis...Pembrolizumab plus pemetrexed-platinum continued to show improved efficacy outcomes compared with placebo plus pemetrexed-platinum, with manageable toxicity.

Median progression-free survival was 8.8 months (95% CI, 7.6 to 9.2) in the pembrolizumab-combination group and 4.9 months (95% CI, 4.7 to 5.5) in the placebo-combination group (hazard ratio for disease progression or death, 0.52; 95% CI, 0.43 to 0.64; P<0.001)....In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a platinum-based drug resulted in significantly longer overall survival and progression-free survival than chemotherapy alone.

Among patients with metastatic nonsquamous NSCLC treated with first-line pembrolizumab + pemetrexed-platinum, early TSC of 30% was the optimal cutoff associated with OS, consistent with RECIST ORR. Deeper response did not have greater association with OS than the 30% RECIST cutoff. ORR by RECIST coupled with DOR explained ~60% of OS benefit from pembrolizumab + pemetrexed-platinum over pemetrexedplatinum alone.